Key factors
sym | MNTA |
exch | US |
MCap | 6.243B |
Beta | 1.785 |
EPS | -2.44 |
Div date | 0000-00-00 |
Yesterday
sym | MNTA |
exch | US |
50 Day MA | 52.27 |
200 Day MA | 36.62 |
52 Week High | 52.53 |
52 Week Low | 13.56 |
Target Price | 52.5 |
Market Cap Mln | 6243.28 |
Share statistics
Shares Outstanding | 118.96M |
Shares Float | 115.22M |
Percent Institutions | 103.48 |
PercentInsiders | 0.984 |
SharesShort | 5413.39K |
Short Ratio | 0.79 |
Shares Short Prior Month | 4400.54K |
Short Percent | 7.569 |
Short Percent Float | 7.569 |
Short Percent Outstanding | 5.000 |
Income
Revenue TTM | 30.07M |
Revenue Per Share TTM | 0.276 |
Quarterly Revenue Growth YOY | 27.59 |
Gross Profit TTM | -73.7M |
EBITDA | -190.8M |
Diluted Eps TTM | -2.09 |
earning
Operating Margin TTM | -8.15 |
EPS Estimate Current Year | -1.76 |
EPS Estimate Next Year | -1.91 |
Earnings Share | -2.44 |
Dividend
Dividend Date | 0000-00-00 |
Last Split Date | 0000-00-00 |
business
Enterprise Value Revenue | 194.33 |
Book Value /share | 3.406 |
Price Book MRQ | 15.79 |
Price Sales TTM | 190.02 |
ReturnOnAssetsTTM | -0.30 |
ReturnOnEquityTTM | -0.64 |
Sector
Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
Gic Industry | Biotechnology |
Gic Sector | Health Care |
Gic Sub Industry | Biotechnology |
Industry | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
Codes
ISIN | US60877T1007 |
CIK | 0001235010 |
Code | MNTA |
CUSIP | 60877T100 |
Employer Id Number | 04-3561634 |
CountryISO | US |
Currency Code | USD |
Currency Name | US Dollar |
Exchange | NASDAQ |
Currency Symbol | $ |
fund
Type | Common Stock |
UpdatedAt | 2020-10-12 |
Home Category | Domestic |
info
Fiscal Year End | December |
Full Time Employees | 118.0 |
IPODate | 2004 |
International Domestic | Domestic |
MostRecent Quarter | 2020-06-30 |
Contact
Name | Momenta Pharmaceuticals, Inc |
Address | 301 Binney Street, Cambridge, MA, United States, 02142 |
Country Name | USA |
Phone | 617 491 9700 |
Web URL | www.momentapharma.com |
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy. The company's biosimilar programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M710, a biosimilar of EYLEA for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema (DME), and diabetic retinopathy in patients with DME. Its complex generics programs include Enoxaparin sodium injection, a generic version of LOVENOX that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing forms of multiple sclerosis; and GLATOPA, a generic version of three-times-weekly COPAXONE. The company has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts. As of September 30, 2020, Momenta Pharmaceuticals, Inc. operates as a subsidiary of Johnson & Johnson.